SEC 13F Intelligence

Broadwood Capital Inc / LCTX

Broadwood Capital Inc’s Lineage Cell Therapeutics In Position

Does Broadwood Capital Inc own Lineage Cell Therapeutics In (LCTX)? Yes — 49.56M shares worth $78M (+5.52% of its 13F portfolio) as of Q1 2026.

Position Value
$78M
Q1 2026
Shares
49.56M
% of Portfolio
+5.52%
Quarters Held
27
currently held

Position History LCTX

Reported value by quarter
Q3 ’19: $33MQ3 ’19Q4 ’19: $30MQ1 ’20: $28MQ2 ’20: $30MQ3 ’20: $32MQ3 ’20Q4 ’20: $60MQ1 ’21: $80MQ2 ’21: $97MQ3 ’21: $86MQ3 ’21Q4 ’21: $83MQ1 ’22: $54MQ2 ’22: $55MQ3 ’22: $39MQ3 ’22Q4 ’22: $41MQ1 ’23: $52MQ2 ’23: $49MQ3 ’23: $41MQ3 ’23Q4 ’23: $38MQ1 ’24: $62MQ2 ’24: $42MQ3 ’24: $38MQ3 ’24Q4 ’24: $21MQ1 ’25: $22MQ2 ’25: $45MQ3 ’25: $84MQ3 ’25Q4 ’25: $83MQ1 ’26: $78Mfilingsflow.com
QuarterSharesValue% of Portfolio
Q1 202649.56M$78M+5.52%
Q4 202549.56M$83M+4.86%
Q3 202549.56M$84M+5.04%
Q2 202549.56M$45M+2.86%
Q1 202549.56M$22M+1.81%
Q4 202441.67M$21M+1.64%
Q3 202441.67M$38M+2.89%
Q2 202441.67M$42M+3.14%
Q1 202441.67M$62M+4.63%
Q4 202334.94M$38M+3.25%
Q3 202334.94M$41M+3.67%
Q2 202334.94M$49M+3.68%
Q1 202334.94M$52M+3.69%
Q4 202234.94M$41M+3.42%
Q3 202234.94M$39M+3.01%
Q2 202234.94M$55M+4.16%
Q1 202234.94M$54M+3.88%
Q4 202134.01M$83M+5.12%
Q3 202134.01M$86M+4.37%
Q2 202134.01M$97M+4.33%
Q1 202134.01M$80M+4.25%
Q4 202034.01M$60M+3.55%
Q3 202034.01M$32M+2.50%
Q2 202034.01M$30M+2.31%
Q1 202034.01M$28M+3.29%
Q4 201934.01M$30M+3.49%
Q3 201934.01M$33M+4.63%

Common-stock position only; options are excluded. Quarters where the fund filed no 13F or reported no position are absent. See Broadwood Capital Inc’s full portfolio or all institutional holders of LCTX.